# Study of SA+X in the Treatment of Newly Diagnosed AML

> **NCT07548710** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 205 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Anthracycline
- **DRUG:** Ivosidenib
- **DRUG:** Gilteritinib
- **DRUG:** Sonrotoclax
- **DRUG:** Azacitidine (AZA)

## Key facts

- **NCT ID:** NCT07548710
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-05-31
- **Final completion:** 2028-12-21
- **Target enrollment:** 205 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07548710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07548710, "Study of SA+X in the Treatment of Newly Diagnosed AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07548710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*